Scientific Publications
Updated December 1, 2023
These scientific publications are authored or co-authored by CDC scientists and/or funded by CDC’s Global Immunization Division, Center for Global Health.
Global Immunization
2023
The use of adaptive sampling to reach disadvantaged populations for immunization programs and assessments: A systematic review.
Kohuncu A, Ishizumi A, Daniels D, Jalloh MF, Wallace AS, Prybylski D. Vaccines (Basel). 2023;11(2):424.
Population-Based Linked Longitudinal Surveillance of Pregnant People and Their Infants: A Critical Resource for Emerging, Re-Emerging, and Persistent Threats.
Tong V, Woodworth K, Blau E, et al. Journal of Women’s Health. 2023;32(1):1-9. doi: 10.1089/jwh.2022.0419.
2022
The future of infodemic surveillance as public health surveillance.
Chiou H, Voegeli C, Wilhelm E, Kolis J, Brookmeyer K, Prybylski D. Emerging Infectious Diseases. 2022;28(Suppl 13):121-128. doi: /10.3201/eid2813.220696.
Comprehensive vaccine-preventable disease surveillance in the Western Pacific Region: A literature review on integration of surveillance functions, 2000-2021.
Donadel M, Scobie H, Pastore R, et al. Global Health Science and Practice. 2022;10(5):e2200017. doi: 10.9745/GHSP-D-22-00017.
Qualitative assessment of caregiver experiences when navigating childhood immunisation in urban communities in Sierra Leone.
Jalloh M, Patel P, Sutton R, et al. BMJ Open. 2022;12(5):e058203. doi: 10.1136/bmjopen-2021-058203.
A global comprehensive vaccine-preventable disease surveillance strategy for the immunization agenda 2030.
Patel MK, Scobie HM, Serhan F, et al. Vaccine. 2022; available online 21 October 2022. doi: 10.1016/j.vaccine.2022.07.024.
Routine Vaccination Coverage – Worldwide, 2021
Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha SV, and Wallace A. MMWR Morb Mortal Wkly Rep. 2022;71(44):1396-1400. doi: 0.15585/mmwr.mm7144a2.
Policy and practice of checking vaccination status at school in 2018, a global overview.
Sadigh K, Fox G, Khetsuriani N, Gao H, Shendale S, Ward K. Vaccine. 2022;40(16):2432-2441. doi: 10.1016/j.vaccine.2022.03.002.
A review of health-related quality of life associated with pneumococcal disease: Pooled estimates by age and type of disease.
Tang Z, Matanock A, Jeon S, et al. J Public Health. 2022;44(2):e234–e240. doi: 10.1093/pubmed/fdab159.
Head-to-head comparison of the immunogenicity of RotaTeq and Rotarix rotavirus vaccines and factors associated with seroresponse in infants in Bangladesh: A randomised, controlled, open-label, parallel, phase 4 trial.
Velasquez-Portocarrero DE, Wang X, Cortese MM, et al. Lancet Infect Dis. 2022;S1473-3099(22)00368-1. doi: 10.1016/S1473-3099(22)00368-1.
Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
Utazi C. E, Aheto J M.K., Wigley A, et al. Vaccine. 2022; 41(1):170-181. doi: 10.1016/j.vaccine.2022.11.026.
2021
Maternal knowledge, attitude, and perception about childhood routine immunization program in Atakumosa-west local government area, Osun State, southwestern Nigeria.
Adedire EB, Ajumobi O, Bolu O, Nguku P, Ajayi O. Pan Afr Med J. 2021;40(1):8. doi: 10.11604/pamj.supp.2021.40.1.30876.
Modeling the impact of vaccination for the Immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021-2030.
Carter A, Msemburi W, Yoon Sim S, Gaythorpe KAM, Lindstrand A, Hutubessy RCW.
Routine vaccination coverage – Worldwide, 2020.
Muhoza P, Danovaro-Holliday MC, Diallo MS, et al. MMWR Morb Mortal Wkly Rep. 2021;29;70(43):1495-1500. doi: 10.15585/mmwr.mm7043a1.
Effect of delays in maternal access to healthcare on neonatal mortality in Sierra Leone: A social autopsy case-control study at a Child Health and Mortality Prevention Surveillance (CHAMPS) site.
Preslar JP, Worrell MC, Kaiser R, et al. Matern Child Health J. 2021;25(8):1326-1335. doi: 10.1007/s10995-021-03132-4.
2020
Global vaccine action plan lessons learned I: recommendations for the next decade.
MacDonald N, Mohsni E, Al-Mazrou Y, et al. Vaccine. 2020;38(33):5364–5371. doi: 10.1016/j.vaccine.2020.05.003.
2019
Routine vaccination coverage — Worldwide, 2019.
Chard AN, Gacic-Dobo M, Diallo MS, Sodha SV, Wallace AS. MMWR Morb Mortal Wkly Rep. 2000;69:1706–1710. doi: 10.15585/mmwr.mm6945a7.
Global routine vaccination coverage, 2018.
Peck M, Gacic-Dobo M, Diallo MS, Nedelec Y, Sodha SS, Wallace AS. MMWR Morb Mortal Wkly Rep. 2019;68(42):937–942. [Erratum in: MMWR Morb Mortal Wkly Rep. 2019;68(44):1010.] doi: 10.15585/mmwr.mm6842a1.
2022
Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
Hidle A, Brennan T, Garon A, et al. Vaccine. 2022;S0264-410X(22)00047-0. doi: 10.1016/j.vaccine.2022.01.024.
WHO-led consensus statement on vaccine delivery costs.
Levin A, Boonstoppel L, Brenzel L, et al. BMC Med. 2022;20(1):88. doi: 10.1186/s12916-022-02278-4.
2021
An assessment of the contribution of National Stop Transmission of Polio Program to Nigeria’s Immunization Program.
Biya O, Archer WR, Rayner J, et al. Pan African Medical Journal. 2021;40(1):1.doi: 10.11604/pamj.supp.2021.40.1.15816.
Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
Brennan T, Hidle A, Doshi RH, et al. Vaccine. 2021;S0264-410X(21)01531-0. doi: 10.1016/j.vaccine.2021.11.057.
A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.
Cox SN, Wedlock PT, Pallas SW, et al. Vaccine. 2021;39(46):6796-6804. doi: 10.1016/j.vaccine.2021.05.033.
Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations.
Ozawa S, Yemeke T, Mitgang E, et al. Vaccine. 2021;39(33):4598-4610. doi: 10.1016/j.vaccine.2021.05.019.
Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers.
Yemeke TT, Mitgang E, Wedlock PT, et al. Vaccine. 2021;39(32):4437-4449. doi: 10.1016/j.vaccine.2021.05.075.
2020
Decision-making and implementation of the first public sector introduction of typhoid conjugate vaccine — Navi Mumbai, India, 2018.
Date K, Shimpi R, Luby S, et al. Clinical Infectious Diseases. 2020;71(S2):S172-78. doi: 10.1093/cid/ciaa597.
Health services uptake among nomadic pastoralist populations in Africa: A systematic review of the literature.
Gammino VM, Diaz MR, Pallas SW, Greenleaf AR, Kurnit MR. PLoS Neglected Tropical Diseases. 2020;14(7):e0008474. doi: 10.1371/journal.pntd.0008474.
Typhoid and paratyphoid cost of illness in Nepal: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II.
Mejia N, Abimbola T, Andrews JR, et al. Clinical Infectious Diseases. 2020;71(S3):S306-18. doi: 10.1093/cid/ciaa1335.
Typhoid and paratyphoid cost of illness in Bangladesh: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project (SEAP) II.
Mejia N, Pallas SW, Saha S, et al. Clinical Infectious Diseases. 2020;71(S3):S293-S305. doi: 10.1093/cid/ciaa1334.
Typhoid and paratyphoid cost of illness in Pakistan: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project (SEAP) II.
Mejia N, Qamar F, Yousafzai MT, et al. Clinical Infectious Diseases. 2020;71(S3):S319-35. doi: 10.1093/cid/ciaa1336.
Methodological considerations for cost of illness studies of enteric fever.
Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Clinical Infectious Diseases. 2020; 71(S2):S111-19. doi: 10.1093/cid/ciaa481.
Financial cost analysis of a strategy to improve the quality of administrative vaccination data in Uganda.
Ward K, Mugenyi K, MacNeil A, et al. Vaccine. 2020;38(5):1105-13. doi: 10.1016/j.vaccine.2019.11.030.
2019
A systematic review of vaccine preventable disease surveillance cost studies.
Erondu NA, Ferland L, Haile BH, Abimbola T. Vaccine. 2019;37(17):2311-21. doi: 10.1016/j.vaccine.2019.02.026.
Selective hepatitis b birth dose vaccination in Sao Tome and Principe: A program assessment and cost-effectiveness study.
Hagan JE, Carvalho E, Souza V, et al. American Journal of Tropical Medicine and Hygiene. 2019;101(4):891-98. doi: 10.4269/ajtmh.18-0926.
Economic value of immunizing geographically hard-to-reach populations with measles vaccine in Kenya.
Lee BY, Brown ST, Haidari LA, et al. Vaccine. 2019;37(17):2377-86. doi: 10.1016/j.vaccine.2019.03.007.
Assessment of economic burden of concurrent measles and rubella outbreaks in Romania, 2011-2012.
Njau J, Janta D, Stanescu A, et al. Emerging Infectious Diseases. 2019;25(6):1101-09. doi: 10.3201/eid2506.180339.
Defining hard-to-reach populations for vaccination.
Ozawa S, Yemeke TT, Evans DR, Pallas SW, Wallace AS, Lee BY. Vaccine. 2019;37(37):5525-34. doi: 10.1016/j.vaccine.2019.06.081.
Program cost analysis of influenza vaccination of health care workers in Albania.
Pallas SW, Ahmeti A, Morgan W, et al. Vaccine. 2019;38(2):220-27. doi: 10.1016/j.vaccine.2019.10.027.
2023
Implementing the immunization agenda 2030: A framework for action through coordinated planning, monitoring & evaluation, ownership & accountability, and communications & advocacy.
Lindstrand A; Mast E, Churchill S, et al. Vaccine. 2023;S0264-410X(21)01236-6. doi: 10.1016/j.vaccine.2021.09.045.
2022
Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: A qualitative study in four regions.
Aborigo R, Welaga P, Oduro A, et al. PLoS One. 2022;17(12):e0277197. doi: 10.1371/journal.pone.0277197.
Data management needs assessment for the scale-up of district health information system and introduction of routine (essential) immunization module in Bauchi State, Nigeria, 2015.
Adeoye O, Adegoke O, Nnadi C, et al. Pan Afr Med J. 2022;40(1):13. doi: 10.11604/pamj.supp.2022.40.1.32458.
Association of community engagement with vaccination confidence and uptake: A cross-sectional survey in Sierra Leone, 2019.
Jalloh M, Sengeh P, Ibrahim N, et al. J Glob Health. 2022;12:04006. doi: 10.7189/jogh.12.04006.
WHO competency framework for health authorities and institutions to manage infodemics: Its development and features.
Rubinelli S, Purnat TD, Wilhelm E, et al. Hum Resour Health. 2022;20(1):49. doi: 10.1186/s12960-022-00750-z.
2021
A rapid qualitative assessment of barriers associated with uptake of routine immunization and recommendations to improve immunization services in Sokoto State, Northwest Nigeria, 2017.
Abad N, Uba B, Patel P, et al. Pan Afr Med J. 2021;40(1):10. doi: 10.11604/pamj.supp.2021.40.1.23793.
Building the Sierra Leone ebola database: Organization and characteristics of data systematically collected during 2014–2015 Ebola epidemic.
Agnihotri S, Alpren C, Bangura B, et al. Ann Epidemiol. 2021;60:35-44. doi: 10.1016/j.annepidem.2021.04.017.
Improving routine immunization data quality using daily short message system reporting platform: An experience from Nasarawa State, Nigeria.
Akerele A, Uba B, Aduloju M, et al. PLoS One. 2021;16(8):e0255563. doi: 10.1371/journal.pone.0255563.
Vaccination information, motivations, and barriers in the context of meningococcal serogroup a conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.
Aksnes BN, Walldorf JA, Nkwenkeu SF, et al. Vaccine. 2021;39(43):6370-6377. doi: 10.1016/j.vaccine.2021.09.038.
Implementation of integrated supportive supervision in the context of coronavirus 19 pandemic: Its effects on routine immunization and vaccine preventable surveillance diseases indicators in the East and Southern African countries.
Bello IM, Lebo E, Shibeshi ME, et al. Pan Afr Med J. 2021;38:164. doi: 10.11604/pamj.2021.38.164.27349.
Infodemics: A new challenge for public health.
Briand SC, Cinelli M, Nguyen T, et al. Cell. 2021;184(25):6010-6014. doi: 10.1016/j.cell.2021.10.031.
A public health research agenda for managing infodemics: Methods and results of the first WHO Infodemiology Conference.
Calleja N, Abdallah A, Abad N, et al. JMIR Infodemiology. 2021;1(1):e30979. doi: 10.2196/30979.
National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.
Donadel M, Panero MS, Ametewee L, Shefer AM. Vaccine. 2021;39(14):1897-1909. doi: 10.1016/j.vaccine.2021.02.059.
Ancillary benefits of seasonal influenza vaccination in middle-income countries.
Ebama MS, Chu SY, Azziz-Baumgartner E, et al. Vaccine. 2021;39(14):1892-1896. doi: 10.1016/j.vaccine.2021.02.048.
Evaluating a mobile phone-delivered text message reminder intervention to reduce infant vaccination dropout in Arua, Uganda: Protocol for a randomized controlled trial.
Ehlman DC, Magoola J, Tanifum P, et al. JMIR Res Protoc. 2021;10(2):e17262. doi: 10.2196/17262.
Community health workers' experiences in strengthening the uptake of childhood immunization and malaria prevention services in urban Sierra Leone.
Ishizumi A, Sutton R, Mansaray A, et al. Front Public Health. 2021;9:767200. doi: 10.3389/fpubh.2021.767200.
Using immunisation caregiver journey interviews to understand and optimise vaccination uptake: Lessons from Sierra Leone.
Jalloh MF, Hickler B, Parmley LE, et al. BMJ Glob Health. 2021;6(5):e005525. doi: 10.1136/bmjgh-2021-005525.
Behaviour adoption approaches during public health emergencies: Implications for the COVID-19 pandemic and beyond.
Jalloh MF, Nur AA, Nur SA, et al. BMJ Global Health. 2021;6(1):e004450. doi: 10.1136/bmjgh-2020-004450.
Trends in classifying vaccine hesitancy reasons reported in the WHO/UNICEF Joint Reporting Form, 2014–2017: Use and comparability of the vaccine hesitancy matrix.
Kulkarni S, Harvey B, Prybylski D, Jalloh MF. Hum Vaccin Immunother. 2021;17(7):2001-2007. doi: 10.1080/21645515.2020.1859319.
Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (ipti) in Kambia District to inform national scale-up in Sierra Leone.
Lahuerta M, Sutton R, Mansaray A, et al. Malar J. 2021;20(1):74. doi: 10.1186/s12936-021-03615-3.
Mapathons versus automated feature extraction: A comparative analysis for strengthening immunization microplanning.
Mendes A, Palmer T, Berens A, et al. Int J Health Geogr. 2021;20(1):27. doi: 10.1186/s12942-021-00277-x.
The global landscape of pediatric bacterial meningitis data reported to the World Health Organization: Coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014-2019.
Nakamura T, Cohen AL, Schwartz S, et al. J Infect Dis. 2021;224(12 Suppl 2):S161-S173. doi: 10.1093/infdis/jiab217.
Enhancing surveillance through the use of acute flaccid paralysis surveillance reminder cards during Immunization Plus Days, December, 2014: A pilot survey in Jigawa State.
Okeke LA, Waziri N, Gidado S, et al. Pan Afr Med J. 2021;40(1):4. doi: 10.11604/pamj.supp.2021.40.1.19647.
Global rotavirus and pneumococcal conjugate vaccine introductions and the association with country disease surveillance, 2006-2018.
Peck ME, Hampton LM, Antoni S, et al. J Infect Dis. 2021;224(12 Suppl 2):S184-S193. doi: 10.1093/infdis/jiab069.
Progress in immunization safety monitoring — Worldwide, 2010-2019.
Salman O, Topf K, Chandler R, Conklin L. MMWR Morb Mortal Wkly Rep. 2021;70(15):547-551. doi: 10.15585/mmwr.mm7015a2.
Use of a district health information system 2 routine immunization dashboard for immunization program monitoring and decision making, Kano State, Nigeria.
Tchoualeu D, Elmousaad H, Osadebe L, et al. Pan Afr Med J. 2021;40(1):2. doi: 10.11604/pamj.supp.2021.40.1.17313.
Evaluation of the impact of immunization second year of life training interventions on health care workers in Ghana.
Tchoualeu DD, Harvey B, Nyaku M, et al. Glob Health Sci Pract. 2021;9(3):498-507. doi: 10.9745/ghsp-d-21-00091.
Applying adult learning best practices to design immunization training for health care workers in Ghana.
Traicoff D, Tchoualeu DD, Opare J, et al. Glob Health Sci Pract. 2021;9(3)487-497. doi: 10.9745/ghsp-d-21-0009.
Modeling optimal laboratory testing strategies for bacterial meningitis surveillance in Africa.
Walker J, Soeters HM, Novak R, et al. J Infect Dis. 2021;224(12 Suppl 2):S218-S227. doi: 10.1093/infdis/jiab154.
Improving supervision practices in resource-limited settings: Opportunities to sustain short-term gains from external technical support.
Weiss D, Sandhu H, Fleming M, Lee CW. Vaccine. 2021;39(34):4772-4774. doi: 10.1016/j.vaccine.2021.06.064.
2020
The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization.
Badizadegan K, Goodson JL, Rota PA, Thompson KM. Expert Rev Vaccines. 2020;19(2):175–194. doi: 10.1080/14760584.2020.1732215.
Vaccination of contacts of Ebola virus disease survivors to prevent further transmission.
Doshi RH, Fleming M, Mukoka AK, et al. Lancet Glob Health. 2020;8(12):e1455-e1456. doi: 10.1016/s2214-109x(20)30454-x.
Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.
School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008-2017.
Feldstein LR, Fox G, Shefer A, Conklin LM, Ward K. Vaccine. 2020;38(3):680-689. doi: 10.1016/j.vaccine.2019.10.054.
Access, demand, and utilization of childhood immunization services: A cross-sectional household survey in Western Area Urban district, Sierra Leone, 2019.
Feldstein LR, Sutton R, Jalloh MF, et al. J Glob Health. 2020;10(1):010420. doi: 10.7189/jogh.10.010420.
Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana.
Gidudu JF, Shaum A, Dodoo A, et al. Vaccine. 2020;38(5):1009-1014. doi: 10.1016/j.vaccine.2019.11.050.
Strengthening National Immunization Technical Advisory Groups in resource-limited settings: Current and potential linkages with polio national certification committees.
Greene SA, Anya B-PM, Asghar H, et al. Health Res Policy Syst. 2020;18(1):116. doi: 10.1186/s12961-020-00632-7.
Assessment of in-country capacity to maintain communicable disease surveillance and response services after polio eradication-Somalia.
Hsu CH, Harvey B, Mohamed A, Elfakki E, Ehrhardt D, Farag NH. Vaccine. 2020;38(5):1220-1224. doi: 10.1016/j.vaccine.2019.11.008.
Assessment of VaxTrac electronic immunization registry in an urban district in Sierra Leone: Implications for data quality, defaulter tracking, and policy.
Jalloh MF, Namageyo-Funa A, Gleason B, et al. Vaccine. 2020;38(39):6103-6111. doi: 10.1016/j.vaccine.2020.07.031.
Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone.
Jalloh MF, Wallace AS, Bunnell RE, et al. Vaccine. 2020;38(22):3854-3861. doi: 10.1016/j.vaccine.2020.03.044.
Qualitative insights into reasons for missed opportunities for vaccination in Kenyan health facilities.
Li AJ, Tabu C, Shendale S, et al. PLoS One. 2020;15(3):e0230783. doi: 10.1371/journal.pone.0230783.
Screening for malaria antigen and anti-malarial IGG antibody in forcibly-displaced Myanmar Nationals: Cox’s Bazar District, Bangladesh, 2018.
Lu A, Cote O, Dimitrova SD, et al. Malar J. 2020;19(1):130. doi: 10.1186/s12936-020-03199-4.
Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717-1725. doi: 10.4269/ajtmh.20-0112.
Building immunization decision-making capacity within the World Health Organization European Region.
Mosina L, Sankar Datta S, Shefer A, et al. Vaccine. 2020;38(33):5109-5113. doi: 10.1016/j.vaccine.2020.05.077.
Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries.
Mungwira RG, Guillard C, Saldaña A, et al. PLoS One. 2020;15(5):e0233334. doi: 10.1371/journal.pone.0233334.
Data on the implementation of VaxTrac electronic immunization registry in Sierra Leone.
Namageyo-Funa A, Jalloh MF, Gleason B, et al. Data Brief. 2020;32:106167. doi: 10.1016/j.dib.2020.106167.
Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso.
Nkwenkeu SF, Jalloh MF, Walldorf JA, et al. BMC Public Health. 2020;20(1):254. doi: 10.1186/s12889-020-8347-z.
The role of National Immunization Technical Advisory Groups (NITAG) in strengthening health system governance: Lessons from three middle-income countries-Argentina, Jordan, and South Africa (2017-2018).
Panero MS, Khuri-Bulos N, Biscayart C, Bonvehi P, Hayajneh W, Madhi SA. Vaccine. 2020;38(45):7118-7128. doi: 10.1016/j.vaccine.2020.08.069.
Improving the quality and use of immunization and surveillance data: Summary report of the Working Group of the Strategic Advisory Group of Experts on Immunization.
Scobie HM, Edelstein M, Nicol E, et al. Vaccine. 2020;38(46):7183-7197. doi: 10.1016/j.vaccine.2020.09.017.
Implementing the routine immunization data module and dashboard of DHIS2 in Nigeria, 2014-2019.
Shuaib F, Garba AB, Meribole E, et al. BMJ Global Health. 2020;5(7):e002203. doi: 10.1136/bmjgh-2019-002203.
Review of the status and challenges associated with increasing influenza vaccination coverage among pregnant women in China.
Zhou S, Greene CM, Song Y, et al. Hum Vaccin Immunother. 2020;16(3):602-611. doi: 10.1080/21645515.2019.1664230.
2019
Supporting national immunization technical advisory groups (NITAG) in resource-contained settings: New strategies and lessons learned from the Task Force for Global Health’s Partnership for Influenza Vaccine Introduction.
Ba-Nguz A, Shah A, Bresee J, et al. Vaccine. 2019;37(38):3646-3653. doi: 10.1016/j.vaccine.2019.05.046.
Developing standardized competencies to strengthen immunization systems and workforce.
Traicoff D, Pope A, Bloland P, et al. Vaccine. 2019;37(11):1428-1435. doi: 10.1016/j.vaccine.2019.01.047.
2022
National Stop Transmission of Polio Program support for polio supplemental immunization activities in Nigeria 2012-2016: Deployment of management support team.
Edukugho AA, Waziri NE, Bolu O, et al. Pan Afr Med J. 2022;40(1):14. doi: 10.11604/pamj.supp.2022.40.1.32562.
2020
The role of the Stop Transmission of Polio (STOP) program in developing countries: The experience of Kenya.
Tesfay B, Makam JK, Sergon K, Onuekwusi I, Muitherero C, Sowe A. BMC Public Health. 2020;20(1):1110. doi: 10.1186/s12889-020-09196-1.
Selection From Previous Years
The Stop Transmission of Polio Data Management (STOP DM) assignment and its role in polio eradication and immunization data improvement in Africa.
Benke A, Williams AJ, MacNeil A. Pan Afr Med J. 2017;27(Suppl 3):20. doi: 10.11604/pamj.supp.2017.27.3.11524.
Lessons learned and legacy of the Stop Transmission of Polio Program.
Kerr Y, Mailhot M, Williams AJ, et al. J Infect Dis. 2017;216(suppl_1):S316-S323. doi: 10.1093/infdis/jix163.
Using the Stop Transmission of Polio (STOP) Program to develop a South Sudan expanded program on immunization workforce.
Tchoualeu DD, Hercules MA, Mbabazi WB, et al. J Infect Dis. 2017;216(suppl_1):S362-S367. doi: 10.1093/infdis/jiw563.
The Global Polio Eradication Initiative Stop Transmission of Polio (STOP) Program — 1999–2013. Centers for Disease Control and Prevention.
MMWR Morb Mortal Wkly Rep. 2013;62(24):501-3.
Vaccine-Preventable Diseases
2023
Behavioral and social drivers of COVID-19 vaccination in the United States, August-November 2021.
Bonner KE, Vashist K, Abad NS, et al. Am J Prev Med. 2023;S0749-3797(23)00016-8. doi: 10.1016/j.amepre.2023.01.014.
Hospitalizations for COVID-19 among American Indian and Alaska Native Adults (≥ 18 Years Old) - New Mexico, March-September 2020.
Hicks J, Burnett E, Matanock A, et al. J Racial Ethn Health Disparities 2023;10(1):56-63. doi: 10.1007/s40615-021-01196-0.
Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria.
Shragai T, Adegoke OJ, Ikwe H, et al. BMJ Global Health. 2023;8(1):e011006. doi: 10.1136/bmjgh-2022-011006.
COVID-19 mortality and progress toward vaccinating older adults — World Health Organization, Worldwide, 2020–2022.
Wong M, Brooks D, Ikejezie J, et al. MMWR Morb Mortal Wkly Rep. 2023;72(5)113–118. doi: 10.15585/mmwr.mm7205a1.
2022
Effects of COVID-19 on vaccine-preventable disease surveillance systems in the World Health Organization Africa Region, 2020.
Bigouette JP, Callaghan AW, Donadel M, et al. Emerg Infect Dis. 2022;28(13):S203-S207. doi: 10.3201/eid2813.220088.
Effect of Nigeria Presidential Task Force on COVID-19 Pandemic, Nigeria.
Bolu O, Mustapha B, Ihekweazu C, et al. Emerg Infect Dis. 2022;28(13):S168-S176. doi: 10.3201/eid2813.220254.
Global responses to the COVID-19 pandemic.
Cassell C, Raghunathan P, Henao O, et al. Emerging Infectious Diseases. 2022;28(Suppl 13):4-7. doi: /10.3201/eid2813.221733.
Past as prologue – Use of rubella vaccination programs lessons to inform COVID-19 vaccination.
Dixon MG, Reef SE, Zimmerman LA, and Grant GB. Emerg Infect Dis. 2022;28(13):S225-S231. doi: 10.3201/eid2813.220604.
Drivers of COVID-19 policy stringency in 175 countries and territories: COVID-19 cases and deaths, gross domestic products per capita, and health expenditures.
Jalloh M, Zeebari Z, Nur S, et al. Journal of Global Health. 2022;12:05049. doi: 10.7189/jogh.12.05049.
COVID-19 vaccination coverage, intentions, attitudes and barriers by race/ethnicity, language of interview, and nativity, National Immunization Survey Adult COVID Module, April 22, 2021-January 29, 2022.
Ohlsen E, Yankey D, Pezzi C, et al. Clin Infect Dis. 2022;ciac508. doi: 10.1093/cid/ciac508.
CDC’s COVID-19 international vaccine implementation and evaluation program and lessons from earlier vaccine introductions.
Soeters HM, Doshi RH, Fleming M, et al. Emerg Infect Dis. 2022;28(13):S208-S216. doi: 10.3201/eid2813.212123.
Coronavirus disease case definitions, diagnostic testing criteria, and surveillance in 25 countries with highest reported case counts.
Suthar AB, Schubert S, Garon J, et al. Emerg Infect Dis. 2022;28(1):148-156. doi: 10.3201/eid2801.211082.
2021
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
Patel MK, Bergeri I, Bresee JS, et al. Vaccine. 2021;39(30):4013-4024. doi: 10.1016/j.vaccine.2021.05.099.
2023
Co-administration of oral cholera vaccine with oral polio vaccine among Bangladeshi young children: A randomized controlled open label trial to assess interference.
Islam M, Date K, Khan A, et al. Clinical Infectious Diseases. 2023; ciac782. doi: 10.1093/cid/ciac782.
Cholera Outbreak — Haiti, September 2022–January 2023.
Ocasio D, Juin S, Berendes D, et al. MMWR Morb Mortal Wkly Rep. 2023; 72(2);21–25. doi: 10.15585/mmwr.mm7202a1.
2022
Co-administration of oral cholera vaccine with oral polio vaccine among Bangladeshi young children: A randomized controlled open label trial to assess interference.
Islam M, Date K, Khan A, et al. Clinical Infectious Diseases. 2022;ciac782. doi: 10.1093/cid/ciac782.
2020
Notes from the field: Cholera outbreak – Zimbabwe, September 2018–March 2019.
Winstead A, Strysko J, Relan P, et al. MMWR Morb Mortal Wkly Rep. 2020;69(17):527-528. doi: 10.15585/mmwr.mm6917a3.
2019
Oral cholera vaccination coverage after the first global stockpile deployment in Haiti, 2014.
Burnett EM, François J, Sreenivasan N, et al. Vaccine. 2019;37(43):6348-6355. doi: 10.1016/j.vaccine.2019.09.018.
Comparing alternative cholera vaccination strategies in Maela refugee camp: using a transmission model in public health practice.
Havumaki J, Meza R, Phares CR, Date K, Eisenberg MC. BMC Infect Dis. 2019;19(1):1075. doi: 10.1186/s12879-019-4688-6.
Selection From Previous Years
Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis.
Bi Q, Ferreras E, Pezzoli L, et al. Lancet Infect Dis. 2017;17(10):1080-1088. doi: 10.1016/S1473-3099(17)30359-6.
Evaluation of knowledge and practices regarding cholera, water treatment, hygiene, and sanitation before and after an oral cholera vaccination campaign-Haiti, 2013-2014.
Childs L, François J, Choudhury A, et al. Am J Trop Med Hyg. 2016;95(6):1305-1313. doi: 10.4269/ajtmh.16-0555.
Oral cholera vaccine coverage during an outbreak and humanitarian crisis, Iraq, 2015.
Lam E, Al-Tamimi W, Russell SP, et al. Emerg Infect Dis. 2017;23(1):38-45. doi: 10.3201/eid2301.160881.
Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
Phares CR, Date K, Travers P, et al. Vaccine. 2016;34(1):128-33. doi: 10.1016/j.vaccine.2015.10.112.
Oral cholera vaccine coverage, barriers to vaccination, and adverse events following vaccination, Haiti, 2013.
Tohme RA, François J, Wannemuehler K, et al. Emerg Infect Dis. 2015;21(6):984-91. doi: 10.3201/eid2106.141797.
Lessons learned from emergency response vaccination efforts for cholera, typhoid, yellow fever, and Ebola.
Walldorf JA, Date KA, Sreenivasan N, Harris JB, Hyde TB. Emerg Infect Dis. 2017;23(13):S210-S216. doi: 10.3201/eid2313.170550.
2023
Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
Choi Y, Lee GS, Li S, et al. Vaccine. 2023; published online May 2023.
2022
Assessing the impact of the routine childhood hepatitis B immunization program and the need for hepatitis B vaccine birth dose in Sierra Leone, 2018.
Breakwell L, Marke D, Kaiser R, et al. Vaccine. 2022;S0264-410X(22)00360-7. doi: 10.1016/j.vaccine.2022.03.049.
Effects of decreased immunization coverage for hepatitis B virus caused by COVID-19 in World Health Organization Western Pacific and African Regions, 2020.
Kabore HJ, Li X, Allison RD, et al. Emerg Infect Dis. 2022;28(13):S217-S224. doi: 10.3201/eid2813.212300.
Progress toward the elimination of mother-to-child transmission of hepatitis B virus – Worldwide, 2016-2021.
Khetsuriani N, Olufunmilayo L, Desai S, Armstrong PA, Tohme RA. MMWR Morb Mortal Wkly Rep. 2022;71:958-963. doi: 10.15585/mmwr.mm7130a2.
Progress towards the elimination of hepatitis B in children in Colombia: A novel two-phase study approach.
Ríos-Hincapié CY, Murad-Rivera R, Tohme RA, et al. J Viral Hepat. 2022;29(9):737-747. doi: 10.1111/jvh.13719.
2021
Progress toward hepatitis B control — World Health Organization European Region, 2016–2019.
Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. MMWR Morb Mortal Wkly Rep. 2021;70:1030-35. doi: 10.15585/mmwr.mm7030a1.
Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017.
Khetsuriani N, Zaika O, Chitadze N, et al. Vaccine. 2021;39:1485-92. doi: 10.1016/j.vaccine.2021.02.004.
Hepatitis B surface antigen seroprevalence among children in the Philippines.
Minta AA, Silva MWT, Shrestha A, et al. Vaccine. 2021;39(14):1982-1989. doi: 10.1016/j.vaccine.2021.02.042.
2020
Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016.
Breakwell L, Anga J, Cooley G, et al. Vaccine. 2020;38(30):4679-4686. doi: 10.1016/j.vaccine.2020.05.029.
An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration.
Gidudu JF, Shaum A, Habersaat K, et al., Vaccine. 2020;38(49):7728-7740. doi: 10.1016/j.vaccine.2019.07.041.
Progress toward hepatitis B control — South-East Asia Region, 2016–2019.
Sandhu HS, Roesel S, Sharifuzzaman M, Chunsuttiwat S, Tohme RA. MMWR Morb Mortal Wkly Rep. 2020;69:988–992. doi: 10.15585/mmwr.mm6930a2.
Social and behavioral determinants of attitudes towards and practices of hepatitis B vaccine birth dose in Vietnam.
Thi Le XT, Ishizumi A, Thu Nguyen HT, et al. Vaccine. 2020;38(52):8343-8350. doi: 10.1016/j.vaccine.2020.11.009.
Evaluation of the efficiency of dried blood spot-based measurement of hepatitis B and hepatitis C virus seromarkers.
Yamamoto C, Nagashima S, Isomura M, et al. Sci Rep. 2020;10(1):3857. doi: 10.1038/s41598-020-60703-1.
2019
Prevalence of chronic hepatitis B virus infection among children in Haiti, 2017.
Childs L, Adrien P, Minta AA, et al. Am J Trop Med Hyg. 2019;101(1):214-219. doi: 10.4269/ajtmh.19-0117.
Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017.
Ork V, Woodring J, Shafiqul Hossain M, et al. Vaccine. 2019;37(35):5059-5066. doi: 10.1016/j.vaccine.2019.06.073.
Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus — Western Pacific Region, 2005–2017.
Woodring J, Pastore R, Brink A, Ishikawa N, Takashima Y, Tohme R. MMWR Morb Mortal Wkly Rep. 2019;68(8);195–200. doi: 10.15585/mmwr.mm6808a2.
Hepatitis B vaccination coverage among health care workers in China.
Yuan Q, Wang F, Zheng H, et al. PLoS One. 2019;14(5):e0216598. doi: 10.1371/journal.pone.0216598.
Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation.
Zhang L, Tao Y, Woodring J, et al. Int J Epidemiol. 2019;48(4):1327-1339. doi: 10.1093/ije/dyz037.
Selection From Previous Years
Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth.
Allison RD, Patel MK, Tohme RA. Vaccine. 2017;35(33):4094-4098. doi: 10.1016/j.vaccine.2017.06.051.
Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation.
Breakwell L, Anga J, Dadari I, Sadr-Azodi N, Ogaoga D, Patel M. Vaccine. 2017;35(21):2770-2774. doi: 10.1016/j.vaccine.2017.04.011.
The status of hepatitis B control in the African Region.
Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. Pan Afr Med J. 2017;27(Suppl 3):17. doi: 10.11604/pamj.supp.2017.27.3.11981.
Improving hepatitis B birth dose coverage through village health volunteer training and pregnant women education.
Li X, Heffelfinger J, Wiesen E, et al. Vaccine. 2017;35(34):4396-4401. doi: 10.1016/j.vaccine.2017.06.056.
Improving hepatitis B birth dose in rural Lao People’s Democratic Republic through the use of mobile phones to facilitate communication.
Xeuatvongsa A, Datta SS, Wannemuehler K, et al. Vaccine. 2016;34(47):5777-5784. doi: 10.1016/j.vaccine.2016.09.056.
2022
Human papillomavirus (HPV) vaccine introduction in low- and lower-middle income countries: Programmatic successes and challenges.
Vaccine. 2022;40 Suppl 1:A1-A124.
Nationwide introduction of HPV vaccine in Zimbabwe 2018–2019: Experiences with multiple cohort vaccination delivery.
Carlton JG, Marembo J, Manangazira P, et al. PLOS Glob Public Health. 2022;2(4):e0000101. doi: 10.1371/journal.pgph.0000101.
Feasibility and acceptability of nationwide HPV vaccine introduction in Senegal: Findings from community-level cross-sectional surveys, 2020.
Doshi RH, Casey RM, Adrien N, et al. PLOS Glob Public Health. 2022;2(4):e0000130. doi: 10.1371/journal.pgph.0000130.
Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo.
Engel D, Afeli AD, Morgan C, et al. Vaccine. 2022;40 Suppl 1:A100-A106. doi: 10.1016/j.vaccine.2021.11.021.
The challenge of identifying eligible girls for HPV vaccination: HPV mapping data verification in Malawi.
Hausi H, Nicks P, Mzengeza T, Tsega A, Khattab D. Vaccine. 2022;40 Suppl 1:A49-A57. doi: 10.1016/j.vaccine.2021.07.025.
Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: a school-based vaccination program targeting multiple cohorts.
Hidle A, Brennan T, Garon J, et al. Vaccine. 2022;S0264-410X(22)00047-0. doi: 10.1016/j.vaccine.2022.01.024.
Using branded behaviour change communication to create demand for the HPV vaccine among girls in Malawi: An evaluation of girl effect’s Zathu Mini Magazine.
Jones A, Kawesa-Newell N. Vaccine. 2022;40 Suppl 1:A107-A115. doi: 10.1016/j.vaccine.2021.07.011.
HPV vaccination coverage in three districts in Zimbabwe following national introduction of 0,12 month schedule among 10 to 14 year old girls.
LaMontagne DS, Manangazira P, Marembo J, et al. Vaccine. 2022;40 Suppl 1:A58-A66. doi: 10.1016/j.vaccine.2021.07.012.
Integration of other services with human papillomavirus vaccination: Lessons from earlier in the life course highlight the need for new policy and implementation evidence.
Morgan C, Giattas MR, Holroyd T, et al. Vaccine. 2022;40 Suppl 1:A94-A99. doi: 10.1016/j.vaccine.2021.12.066.
The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.
Vodicka E, Nonvignon J, Antwi-Agyei KO, et al. Vaccine. 2022;40 Suppl 1:A85-A93. doi: 10.1016/j.vaccine.2021.07.027.
Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
Wirtz C, Mohamed Y, Engel D, et al. Vaccine. 2022;40 Suppl 1:A116-A123. doi: 10.1016/j.vaccine.2021.11.013.
2021
Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India–2018–2019.
Ahmed D, VanderEnde K, Harvey P, et al. Vaccine. 2021;S0264-410X(21)00901-4. doi: 10.1016/j.vaccine.2021.07.024.
Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
Brennan T, Hidle A, Doshi RH, et al. Vaccine. 2021;S0264-410X(21)01531-0. doi: 10.1016/j.vaccine.2021.11.057.
National introduction of HPV vaccination in Senegal—Successes, challenges, and lessons learned.
Casey RM, Adrien N, Badiane O, et al. Vaccine. 2021;S0264-410X(21)01075-6. doi: 10.1016/j.vaccine.2021.08.042.
Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.
Garon JR, Mukavhi A, Rupfutse M, et al. Vaccine. 2021;S0264-410X(21)00669-1. doi: 10.1016/j.vaccine.2021.05.074.
Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction.
Li AJ, Kyesi F, Mwengee W, et al. Vaccine. 2021;S0264-410X(21)00052-9. doi: 10.1016/j.vaccine.2021.01.036.
Tanzania’s human papillomavirus (HPV) vaccination program: Community awareness, feasibility, and acceptability of a national HPV vaccination program, 2019.
Li AJ, Manzi F, Kyesi F, et al. Vaccine. 2021;S0264-410X(21)00797-0. doi: 10.1016/j.vaccine.2021.06.047.
National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
Mphuru A, Anyie JL, Kyesi F, et al. Vaccine. 2021;S0264-410X(21)00472-2. doi: 10.1016/j.vaccine.2021.04.025.
2023
Progress Toward Regional Measles Elimination — Worldwide, 2000–2022.
Minta AA, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep 2023;72:1262–1268. doi: 10.15585/mmwr.mm7246a3.
Progress Toward Measles and Rubella Elimination – Indonesia, 2013-2022.
Chacko S, Kamal M, Endang, BH et al. MMWR Morb Mortal Wkly Rep. 2023:72:1134-1139. doi: 10.15585/mmwr.mm7242a2.
Lessons learnt from the applying the Centers for Disease Control and Prevention (CDC) evaluation framework to the measles incident management system response, USA, 2020–2021.
Jacenko A, Bough S, Grant G, et al. BMJ Glob Health. 2023;8(3):e011861.
Nationwide measles and rubella outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, et al. Open Forum Infect Dis. 2023;10(2):ofad032.
Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
Utazi CE, Aheto JMK, Wigley A, et al. Vaccine. 2023;41(1):170-181. doi: 10.1016/j.vaccine.2022.11.026.
2022
Measles susceptibility in maternal-infant dyads-Bamako, Mali.
Dixon MG, Tapia MG, Wannemuehler K, et al. Vaccine. 2022;S0264-410X(22)00027-5. doi: 10.1016/j.vaccine.2022.01.012.
Accelerating measles elimination in the Western Pacific Region during the calm between the storms.
Durheim D, Baker M, Capeding M, et al. Lancet Reg Health West Pac. 2022;23:100495. doi: 10.1016/j.lanwpc.2022.100495.
Innovations in vaccine delivery: Increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.
Goodson JL, Rota PA. Drug Deliv Transl Res. 2022;12(5):959-967. doi: 10.1007/s13346-022-01130-9.
Progress toward measles elimination — South-East Asia Region, 2003–2020.
Khanal S, Kassem A, Bahl S, et al. MMWR Morb Mortal Wkly Rep. 2022;71(33):1042–1046. doi: 10.15585/mmwr.mm7133a2.
Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic Republic of the Congo.
Knipes AK, Summers A, Sklavounos AA, et al. PLoS One. 2022;17(12):e0278749. doi: 10.1371/jounral.pone.0278749.
Progress toward regional measles elimination — Worldwide, 2000 – 2021.
Minta AA, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep. 2022;71:1489-1495. doi: 10.15585/mmwr.mm7147a1.
Progress toward measles and rubella elimination — India, 2005–2021.
Murugan R, VanderEnde K, Dhawan V, et al. MMWR Morb Mortal Wkly Rep. 2022;71(50):1569–1575. doi: 10.15585/mmwr.mm7150a1.
Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study.
Winter AK, Lambert B, Klein D, et al. Lancet Glob Health. 2022;10(10):E1412-E1422. doi: 10.1016/S2214-109X(22)00335-7.
2021
Development of a measles and rubella multiplex bead serological assay for assessing population immunity.
Coughlin MM, Matson Z, Sowers SB, et al. J Clin Microbiol. 2021;59(6):e02716-20. doi: 10.1128/JCM.02716-20.
Risk factors for measles deaths among children during a nationwide measles outbreak - Romania, 2016-2018.
Donadel M, Stanescu A, Pistol A, et al. BMC Infect Dis. 2021;(1):279. doi: 10.1186/s12879-021-05966-3.
Progress toward measles elimination — Worldwide, 2000-2020.
Dixon MG, Ferrari M, Antoni S, et al. MMWR Morb Mortal Wkly Rep. 2021;70(45):1563-1569. doi: 10.15585/mmwr.mm7045a1.
Measles in the 21st century: Progress toward achieving and sustaining elimination.
Gastañaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. J Infect Dis. 2021;224(Supplement_4):S420-S428. doi: 10.1093/infdis/jiaa793.
Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries.
Gaythorpe KA, Abbas K, Huber J, et al. Elife. 2021;10:e67023. doi: 10.7554/eLife.67023.
Feasibility assessment of measles and rubella eradication.
Moss WJ, Shendale S, Lindstrand A, et al. Vaccine. 2021;39(27):3544-3559. doi: 10.1016/j.vaccine.2021.04.027.
The changing global epidemiology of measles, 2013-2018.
Patel MK, Antoni S, Nedelec Y, et al. J Infect Dis. 2020;222(7):1117-1128. doi: 10.1093/infdis/jiaa044.
2020
Rapid diagnostic tests to address challenges for global measles surveillance.
Brown DW, Warrener L, Scobie HM, et al. Curr Opin Virol. 2020;41:77–84. doi: 10.1016/j.coviro.2020.05.007.
Community-based surveillance in Côte d'Ivoire.
Clara A, Ndiaye SM, Joseph B, et al. Health Secur. 2020;18(S1):S23-S33. doi: 10.1089/hs.2019.0062.
What it will take to achieve a world without measles.
Cochi SL, Schluter WW. J Infect Dis. 2020;222(7):1073–1075. doi: 10.1093/infdis/jiaa045.
Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.
Access, demand, and utilization of childhood immunization services: A cross-sectional household survey in Western Area Urban district, Sierra Leone, 2019.
Feldstein LR, Sutton R, Jalloh MF, et al. J Glob Health. 2020;10(1):010420. doi: 10.7189/jogh.10.010420.
Recent setbacks in measles elimination: The importance of investing in innovations for immunizations.
Goodson JL. Pan Afr Med J. 2020;35(Suppl 1):15. doi: 10.11604/pamj.supp.2020.35.1.21740.
Progress toward measles elimination — Eastern Mediterranean Region, 2013–2019.
Goodson J, Teleb N, Ashmony H, et al. MMWR Morb Mortal Wkly Rep. 2020;69(15):439–445. doi: 10.15585/mmwr.mm6915a2.
Assessment of VaxTrac electronic immunization registry in an urban district in Sierra Leone: implications for data quality, defaulter tracking, and policy.
Jalloh MF, Namageyo-Funa A, Gleason B, et al. Vaccine. 2020;38(39):6103–6111. doi: 10.1016/j.vaccine.2020.07.031.
High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia.
Khetsuriani N, Sanadze K, Abuladze M, Tatishvili N. Clin Microbiol Infect. 2020;26(6):737–742. doi: 10.1016/j.cmi.2019.10.035.
Challenges to achieving measles elimination, Georgia, 2013–2018.
Khetsuriani N, Sanadze K, Chlikadze R, et al. Emerg Infect Dis. 2020;26(11):2565–2577. doi: 10.3201/eid2611.200259.
Risk factors for measles virus infection and susceptibility in persons aged 15 years and older in China: A multi-site case-control study, 2012-2013.
Ma C, Hao L, Rodewald L, et al. Vaccine. 2020;38(16):3210–3217. doi: 10.1016/j.vaccine.2020.03.006.
The African Region early experience with structures for the verification of measles elimination — A review.
Masresha B, Luce R, Tanifum P, Lebo E, Dosseh A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):1. doi: 10.11604/pamj.supp.2020.35.1.19061.
The impact of a prolonged Ebola outbreak on measles elimination activities in Guinea, Liberia, and Sierra Leone, 2014–2015.
Masresha BG, Luce R Jr, Weldegebriel G, Katsande R, Gasasira A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):8. doi: 10.11604/pamj.supp.2020.35.1.19059.
Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717–1725. doi: 10.4269/ajtmh.20-0112.
Action needed now to prevent further increases in measles and measles deaths in the coming years.
Mulholland K, Kretsinger K, Wondwossen L, Crowcroft N. Lancet. 2020;396(10265):1782–1784. doi: 10.1016/S0140-6736(20)32394-1.
Measles and rubella IgG seroprevalence in persons 6 months–35 years of age, Mongolia, 2016.
Nogareda F, Gunregjav N, Sarankhuu A, et al. Vaccine. 2020;38(26):4200–4208. doi: 10.1016/j.vaccine.2020.04.024.
The changing global epidemiology of measles, 2013–2018.
Patel MK, Antoni S, Nedelec Y, et al. J Infect Dis. 2020;222(7):1117–1128. doi: 10.1093/infdis/jiaa044.
Progress toward regional measles elimination — Worldwide, 2000–2019.
Patel MK, Goodson JL, Alexander JP Jr., et al. MMWR Morb Mortal Wkly Rep. 2020;69:1700–1705. doi: 10.15585/mmwr.mm6945a6.
A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination.
Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. Curr Opin Virol. 2020;41:68–76. doi: 10.1016/j.coviro.2020.05.005.
Progress towards measles elimination in Eritrea: 2003–2018.
Yehdego T, Yhdego TK, Masresha B, et al. Pan Afr Med J. 2020;35(Suppl 1):7. doi: 10.11604/pamj.supp.2020.35.1.19126.
2019
Spread of measles in Europe and implications for US travelers.
Angelo KM, Gastañaduy PA, Walker AT, et al. Pediatrics. 2019;144(1):e20190414. doi: 10.1542/peds.2019-0414.
Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B, Hickman C, Icenogle JP, Rota PA. Curr Opin Virol. 2019;34:110-116. doi: 10.1016/j.coviro.2019.01.002.
Use of FTA cards to transport throat swabs and oral fluid samples for molecular detection and genotyping of measles and rubella viruses.
Bankamp B, Sein C, Pukuta Simbu E, et al. J Clin Microbiol. 2019;57(5). doi: 10.1128/JCM.00048-19.
Genetic characterization of measles and rubella viruses detected through global measles and rubella elimination surveillance, 2016–2018.
Brown KE, Rota PA, Goodson JL, et al. MMWR Morb Mortal Wkly Rep. 2019;68(26):587–591. doi: 10.15585/mmwr.mm6826a3.
Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.
Funk S, Knapp JK, Lebo E, et al. BMC Med. 2019;17(1):180. doi: 10.1186/s12916-019-1413-7.
Accelerating measles and rubella elimination through research and innovation — Findings from the Measles & Rubella Initiative research prioritization process, 2016.
Grant GB, Masresha BG, Moss WJ, et al. Vaccine. 2019;37(38):5754-5761. doi: 10.1016/j.vaccine.2019.01.081.
Evaluating vaccination policies to accelerate measles elimination in China: A meta-population modelling study.
[published correction appears in Int J Epidemiol. 2019 Aug 1;48(4):1385].
Hao L, Glasser JW, Su Q, et al. Int J Epidemiol. 2019;48(4):1240-1251. doi: 10.1093/ije/dyz058.
The clinical impact and cost-effectiveness of measles-mumps-rubella vaccination to prevent measles importations among international travelers from the United States.
Hyle EP, Fields NF, Fiebelkorn AP, et al. Clin Infect Dis. 2019;69(2):306-315. doi: 10.1093/cid/ciy861.
Measles and rubella seroprevalence among adults in Georgia in 2015: Helping guide the elimination efforts.
Khetsuriani N, Chitadze N, Russell S, Ben Mamou M. Epidemiol Infect. 2019;147:e319. doi: 10.1017/S0950268819002048.
Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL, Grant GB, Moss WJ, et al. Vaccine. 2019;37(38): 5745–5753. doi: 10.1016/j.vaccine.2019.02.058.
International importations of measles virus into the United States during the postelimination era, 2001–2016.
Lee AD, Clemmons NS, Patel M, Gastañaduy PA. J Infect Dis. 2019;219(10):1616-1623. doi: 10.1093/infdis/jiy701.
Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya.
Lee BY, Brown ST, Haidari LA, et al. Vaccine. 2019;37(17): 2377–2386. doi: 10.1016/j.vaccine.2019.03.007.
Increase in infant measles deaths during a nationwide measles outbreak — Mongolia, 2015–2016.
Lee CT, Hagan JE, Jantsansengee B, et al. J Infect Dis. 2019;220(11):1771-1779. doi: 10.1093/infdis/jiz140.
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14–14–2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y, Chu SY, Yue C, et al. Lancet. 2019;19(4):402–409. doi: 10.1016/S1473-3099(18)30650-9.
Progress toward measles elimination — China, January 2013–June 2019.
Ma C, Rodewald L, Hao L, et al. MMWR Morb Mortal Wkly Rep. 2019;68(48):1112–1116. doi: 10.15585/mmwr.mm6848a2.
Progress toward measles elimination — Pakistan, 2000–2018.
Mere MO, Goodson JL, Chandio AK, et al. MMWR Morb Mortal Wkly Rep. 2019;68(22):505–510. doi: 10.15585/mmwr.mm6822a4.
Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: A systematic review and meta-analysis.
Nic Lochlainn LM, de Gier B, van der Maas N, et al. Lancet Infect Dis. 2019;19(11):1235–1245. doi: 10.1016/S1473-3099(19)30395-0.
Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: A systematic review and meta-analysis.
Nic Lochlainn LM, de Gier B, van der Maas N, et al. Lancet Infect Dis. 2019;19(11):1246–1254. doi: 10.1016/S1473-3099(19)30396-2.
Assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012.
Njau J, Janta D, Stanescu A, et al. Emerg Infect Dis. 2019;25(6):1101–1109. doi: 10.3201/eid2506.180339.
Progress toward regional measles elimination — Worldwide, 2000–2018.
Patel MK, Dumolard L, Nedelec Y, et al. MMWR Morb Mortal Wkly Rep. 2019;68(48):1105–1111. doi: 10.15585/mmwr.mm6848a1.
Classification of global measles cases in 2013–2017 as due to policy or vaccination failure: A retrospective review of global surveillance data.
Patel MK, Orenstein WA. Lancet Glob Health. 2019;7(3):e313–e320. doi: 10.1016/S2214-109X(18)30492-3.
Measles.
Strebel PM, Orenstein WA. N Engl J Med. 2019;381(4):349–357. doi: 10.1056/NEJMcp1905181.
Measles and rubella immunity in the population of Bhutan, 2017.
Wangchuk S, Nogareda F, Tshering N, et al. Vaccine. 2019;37(43):6463–6469. doi: 10.1016/j.vaccine.2019.08.085.
Progress toward measles elimination — European Region, 2009–2018.
Zimmerman LA, Muscat M, Singh S, et al. MMWR Morb Mortal Wkly Rep. 2019;68(17):396–401. doi: 10.15585/mmwr.mm6817a4.
Selection From Previous Years
Progress toward regional measles elimination — Worldwide, 2000–2017.
Dabbagh A, Laws RL, Steulet C, et al. MMWR Morb Mortal Wkly Rep. 2018;67(47):1323–1329. doi: 10.15585/mmwr.mm6747a6.
Progress and challenges in measles and rubella elimination in the WHO European Region.
Datta SS, O'Connor PM, Jankovic D, et al. Vaccine. 2018;36(36):5408–5415. doi: 10.1016/j.vaccine.2017.06.042.
Measles outbreak response decision-making under uncertainty: A retrospective analysis.
Fonnesbeck CJ, Shea K, Carran S, et al. J R Soc Interface. 2018;15(140). doi: 10.1098/rsif.2017.0575.
Measles-Rubella supplementary immunization activity readiness assessment — India, 2017–2018.
Gurnani V, Haldar P, Khanal S, et al. MMWR Morb Mortal Wkly Rep. 2018;67(26):742–746. doi: 10.15585/mmwr.mm6726a3.
Progress toward measles elimination — Western Pacific Region, 2013–2017.
Hagan JE, Kriss JL, Takashima Y, et al. MMWR Morb Mortal Wkly Rep. 2018;67(17):491–495. doi: 10.15585/mmwr.mm6717a3.
A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques.
Joyce JC, Carroll TD, Collins ML, et al. J Infect Dis. 2018;218(1):124–132. doi: 10.1093/infdis/jiy139.
Healthcare-associated measles following a nationwide outbreak in Mongolia.
Lake JG, Luvsansharav UO, Hagan JE, et al. Clin Infect Dis. 2018;67(2):288–290. doi: 10.1093/cid/ciy067.
Global landscape of measles and rubella surveillance.
Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Vaccine. 2018;36(48):7385–7392. doi: 10.1016/j.vaccine.2018.10.007.
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S, Tabu C, N'ganga J, et al. PLoS One. 2018;13(7):e0199786. doi: 10.1371/journal.pone.0199786.
2023
Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2021–December 2022.
Bigouette JP, Henderson E, Traoré M, et al. MMWR Morb Mortal Wkly Rep. 2023;72(14):366-37. doi: 10.15585/mmwr.mm7214a3.
Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022
Biya O, Manu JI, Forbi JC, et al. MMWR Morb Mortal Wkly Rep. 2023;72(47):1290-91. doi: 10.15585/mmwr.mm7247a3.
Progress Toward Poliomyelitis Eradication — Afghanistan, January 2022–June 2023
Bjork A, Akbar IE, Chaudhury S, et al. MMWR Morb Mortal Wkly Rep. 2023;72(38):1020-26. doi: 10.15585/mmwr.mm7238a1.
Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
Darwar R, Biya O, Greene S, et al. Vaccine. 2023:S0264-410X(23)00214-1.
Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023
Davlantes E, Jorba J, Henderson E, et al. MMWR Morb Mortal Wkly Rep. 2023; 72(38);1041–1042. doi: 10.15585/mmwr.mm7238a4.
Update on Wild Poliovirus Type 1 Outbreak — Southeastern Africa, 2021–2022.
Davlantes E, Greene S, Tobolowsly F, et al. MMWR Morb Mortal Wkly Rep. 2023;72(15):391-397. doi: 10.15585/mmwr.mm7215a3.
Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska DA, Wassilak SGF, Wiesen E, et al. Risk Analysis. 2023; 00, 1–13. doi: 10.1111/risa.14158.
Progress Toward Poliomyelitis Eradication — Worldwide, January 2021–March 2023.
Lee S, Greene S, Burns C, et al. MMWR Morb Mortal Wkly Rep. 2023;72(19):517-522. doi: 10.15585/mmwr.mm7219a3.
Polio vaccination activities in conflict-affected areas.
Mbaeyi C. Hum Vaccin Immunother. 2023; 19(2):2237390. doi: 10.1080/21645515.2023.2237390.
Progress Toward Poliomyelitis Eradication — Pakistan, January 2022–June 2023
Mbaeyi C, Baig S, Safdar RM, et al. MMWR Morb Mortal Wkly Rep. 2023;72(33);880–85. doi: 10.15585/mmwr.mm7233a1.
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
Snider CJ, Zaman K, Wilkinson AL. et al. Vaccine. 2023;41(41);6083-92. doi: 10.1016/j.vaccine.2023.08.055
Surveillance To Track Progress Toward Poliomyelitis Eradication — Worldwide, 2021–2022.
Stehling-Ariza T, Wilkinson AL, Diop OM, et al. MMWR Morb Mortal Wkly Rep. 2023;72(23);613–620. doi: 10.15585/mmwr.mm7223a1.
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL, Zaman K, Hoque M, et al. The Lancet Infectious Diseases. 2023;23(9);1062-71. doi.org: 10.1016/S1473-3099(23)00139-1.
2022
Progress toward poliomyelitis eradication – Pakistan, January 2021-July 2022.
Chukwuma M, Baig S, Safdar MR, et al. MMWR Morb Mortal Wkly Rep. 2022;71(42):1313-1318. doi: 10.15585/mmwr.mm7142a1.
Notes from the field: Initial outbreak response activity following wild poliovirus type 1 detection — Malawi, February 2022.
Davlantes E. MMWR Morb Mortal Wkly Rep. 2022;71(23):776–777. doi: 10.15585/mmwr.mm7123a3.
Immunogenicity of reduced-dose monovalent type 2 oral poliovirus vaccine in Mocuba, Mozambique.
de Deus N, Capitine IP, Bauhofer AF, et al. J Infect Dis. 2022;226(2):292-298. doi: 10.1093/infdis/jiaa704.
Community-based survey to assess seroprevalence of poliovirus antibodies in far-north Cameroon in 2020.
Endegue M, Sein C, Cavestany R, et al. Vaccine. 2022;12:10024. doi: 10.1016/j.jvacx.2022.100244.
A survey to assess serological prevalence of poliovirus antibodies in areas with high-risk for vaccine-derived poliovirus transmission in Chad.
Gamougam K, Jeyaseelan V, Jones KAV, et al. J Pediatric Infect Dis Soc. 2022;11(2):55-59. doi: 10.1093/jpids/piab103.
Planning and implementing a targeted polio vaccination campaign for Somali mobile populations in Northeastern Kenya based on migration and settlement patterns.
Harvey B, Dalal W, Amin F, et al. Ethn Health. 2022;27(4):817-832. doi: 10.1080/13557858.2020.1838455.
Outbreak response strategies with type 2-containing oral poliovirus vaccines.
Kalkowska D, Wassilak S, Pallansch M, et al. Vaccine. 2022;S0264-410X(22)01336-6. doi: 10.1016/j.vaccine.2022.10.060.
Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing — Worldwide, March–October 2021.
Martin J, Burns C, Jorba J, et al. MMWR Morb Mortal Wkly Rep. 2022;71(24):786–790. doi: 10.15585/mmwr.mm7124a2.
Progress toward poliomyelitis eradication – Afghanistan, January 2021 – September 2022.
Mohamed A, Akbar IE, Chaudhury S, et al. MMWR Morb Mortal Wkly Rep. 2022;71(49):1541–1546. doi: 10.15585/mmwr.mm7149a1.
Notes from the field: Readiness for use of type 2 novel oral poliovirus vaccine in response to a type 2 circulating vaccine-derived poliovirus outbreak — Tajikistan, 2020–2021.
O’Connor P, Huseynov S, Nielsen CF, et al. MMWR Morb Mortal Wkly Rep. 2022;71(9):361-362. doi: 10.15585/mmwr.mm7109a4.
Progress toward polio eradication — Worldwide, January 2020–April 2022.
Rachlin A, Patel J, Burns C, et al. MMWR Morb Mortal Wkly Rep. 2022;71(19):650-655. doi: 10.15585/mmwr.mm7119a2.
Progress toward poliomyelitis eradication ― Afghanistan, January 2020–November 2021.
Sadigh KS, Akbar IE, Wadood MZ, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):85-89. doi: 10.15585/mmwr.mm7103a3.
Poliovirus immunity among children aged 6-11 and 36-48 months in 14 polio high-risk provinces of Afghanistan: A health-facility-based study.
Soofi S, Martinez M, Farag N, et al. Vaccines (Basel). 2022;10(10):1726. doi: 10.3390/vaccines10101726.
Randomized controlled clinical trial of bivalent oral poliovirus vaccine and inactivated poliovirus vaccine in Nigerian children.
Tagbo BN, Verma H, Mahmud ZM, et al. J Infect Dis. 2022;226(2):299-307. doi: 10.1093/infdis/jiaa726.
Surveillance to track progress toward polio eradication – Worldwide, 2020 – 2021.
Wilkinson AL, Diop OM, Jorba J, Gardner T, Snider CJ, Ahmed J. MMWR Morb Mortal Wkly Rep. 2022;71(15):538-554. doi: 10.15585/mmwr.mm7115a2.
2021
Environmental surveillance for polioviruses in Haiti (2017–2019): The dynamic process for the establishment and monitoring of sampling sites.
Alleman MM, Coulliette-Salmond AD, Wilnique P, et al. Viruses. 2021;13(3):505. doi: 10.3390/v13030505.
Update on vaccine-derived poliovirus outbreaks — Worldwide, January 2020–June 2021.
Alleman MM, Jorba J, Henderson E, et al. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691-1699. doi: 10.15585/mmwr.mm7049a1.
The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
Burkholder B, Wadood Z, Kassem AM, Ehrhardt D, Zomahoun D. Vaccine. 2021. doi: 10.1016/j.vaccine.2021.10.028.
Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010–2020.
Chard AN, Martinez M, Matanock A, Kassem AM. Vaccine. 2021;39(42):6250-6255. doi: 10.1016/j.vaccine.2021.09.020.
The long and winding road to eradicate vaccine-related polioviruses.
Cochi SL, Pallansch MA. J Infect Dis. 2021;223(1):7-9. doi: 10.1093/infdis/jiaa393.
Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options.
Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. J Infect Dis. 2021;224(9):1529-1538. doi: 10.1093/infdis/jiab160.
Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Vaccine. 2021;S0264-410X(21)00543-0. doi: 10.1016/j.vaccine.2021.04.061.
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Kalkowska DA, Voorman A, Pallansch MA, et al. Vaccine. 2021;S0264-410X(21)00473-4. doi: 10.1016/j.vaccine.2021.04.026.
Progress toward poliomyelitis eradication - Pakistan, January 2020-July 2021.
Mbaeyi C, Baig S, Khan Z, et al. MMWR Morb Mortal Wkly Rep. 2021;70(39):1359-1364. doi: 10.15585/mmwr.mm7039a1.
Stopping a polio outbreak in the midst of war: Lessons from Syria.
Mbaeyi C, Moran T, Wadood Z, et al. Vaccine. 2021;39(28):3717-3723. doi: 10.1016/j.vaccine.2021.05.045.
Achieving high poliovirus antibody seroprevalence in areas at risk of vaccine-derived poliovirus transmission-Niger experience.
Ousmane S, Ibrahim DD, Goel A, et al. Open Forum Infect Dis. 2021;8(7):ofab210. doi: 10.1093/ofid/ofab210.
One-year decline of poliovirus antibodies following fractional-dose inactivated poliovirus vaccine.
Saleem AF, Mach O, Yousafzai MT, et al. J Infect Dis. 2021;223(7):1214-1221. doi: 10.1093/infdis/jiaa504.
Surveillance to track progress toward polio eradication — Worldwide, 2019-2020.
Tuma JN, Wilkinson AL, Diop OM, et al. MMWR Morb Mortal Wkly Rep. 2021;70(18):667-673. doi: 10.15585/mmwr.mm7018a2.
2020
Update on vaccine-derived poliovirus outbreaks — Worldwide, July 2019–February 2020.
Alleman MM, Jorba J, Greene SA, et al. MMWR Morb Mortal Wkly Rep. 2020;69(16):489-495. doi: 10.15585/mmwr.mm6916a1.
Progress toward polio eradication — Worldwide, January 2018–March 2020.
Chard AN, Datta SD, Tallis G, et al. MMWR Morb Mortal Wkly Rep. 2020;69(25):784-789. doi: 10.15585/mmwr.mm6925a4.
Assessment of immunity to polio among Rohingya children in Cox’s Bazar, Bangladesh, 2018: A cross-sectional survey.
Estivariz CF, Bennett SD, Lickness JS, et al. PLOS Med. 2020;17(3). doi: 10.1371/journal.pmed.1003070.
Progress toward poliomyelitis eradication — Pakistan, January 2019−September 2020.
Hsu CH, Rehman MS, Bullard K, et al. MMWR Morb Mortal Wkly Rep. 2020;69(46):1748-1752. doi: 10.15585/mmwr.mm6946a5.
Modeling poliovirus transmission in Borno and Yobe, Northeast Nigeria.
Kalkowska DA, Franka R, Higgins J, et al. Risk Anal. 2020;41(2):289-302. doi: 10.1111/risa.13485.
Updated characterization of post‐OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart.
Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SG, Thompson KM. Risk Anal. 2020;41(2):320-328. doi: 10.1111/risa.13555.
Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame.
Kalkowska DA, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Risk Anal. 2020;41(2):248-265. doi: 10.1111/risa.13447.
Updated characterization of outbreak response strategies for 2019–2029: Impacts of using a novel type 2 oral poliovirus vaccine strain.
Kalkowska DA, Pallansch MA, Wilkinson A, et al. Risk Anal. 2020;41(2):329-348. doi: 10.1111/risa.13622.
Surveillance to track progress toward polio eradication — Worldwide, 2018–2019.
Lickness JS, Gardner T, Diop OM, et al. MMWR Morb Mortal Wkly Rep. 2020;69(20):623-629. doi: 10.15585/mmwr.mm6920a3.
Update on immunodeficiency-associated vaccine-derived polioviruses — Worldwide, July 2018–December 2019.
Macklin G, Diop OM, Humayun A, et al. MMWR Morb Mortal Wkly Rep. 2020;69(28):913-917. doi: 10.15585/mmwr.mm6928a4.
Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine.
Macklin GR, O’Reilly KM, Grassly NC, et al. Science. 2020;368(6489):401-405. doi: 10.1126/science.aba1238.
Estimating population immunity to poliovirus in Lebanon: Results from a seroprevalence survey, 2016.
Mansour Z, Said R, Wannemuehler K, et al. Vaccine. 2020;38(31):4846-4852. doi: 10.1016/j.vaccine.2020.05.052.
Progress toward poliomyelitis eradication — Afghanistan, January 2019–July 2020.
Martinez M, Akbar IE, Wadood MZ, Shukla H, Jorba J, Ehrhardt D. MMWR Morb Mortal Wkly Rep. 2020;69(40):1464-1468. doi: 10.15585/mmwr.mm6940a3.
Notes from the field: CDC polio surge response to expanding outbreaks of type 2 circulating vaccine-derived poliovirus — Africa and Philippines, September 2019–March 2020.
Meyer E, Sikka N, Durry E, Datta D. MMWR Morb Mortal Wkly Rep. 2020;69(34):1182-1183. doi: 10.15585/mmwr.mm6934a6.
Progress toward poliovirus containment implementation — Worldwide, 2019–2020.
Moffett DB, Llewellyn A, Singh H, et al. MMWR Morb Mortal Wkly Rep. 2020;69(37):1330-1333. doi: 10.15585/mmwr.mm6937a7.
Immunogenicity of intramuscular fractional dose of inactivated poliovirus vaccine.
Resik S, Mach O, Tejeda A, et al. J Infect Dis. 2020;221(6):895-901. doi: 10.1093/infdis/jiz323.
New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicators.
VanderEnde K, Voorman A, Khan S, et al. Vaccine: X. 2020;4:100059. doi: 10.1016/j.jvacx.2020.100059.
2019
Estimating population immunity to poliovirus in Jordan’s high-risk areas.
Farag NH, Wannemuehler K, Weldon W, et al. Hum Vaccin Immunother. 2019;16(3):548-553. doi: 10.1080/21645515.2019.1667727.
2023
Progress Toward Measles and Rubella Elimination – Indonesia, 2013-2022.
Chacko S, Kamal M, Endang, BH et al. MMWR Morb Mortal Wkly Rep. 2023:72:1134-1139. doi: 10.15585/mmwr.mm7242a2
Estimates of the global burden of Congenital Rubella Syndrome, 1996-2019.
Vynnycky E, Knapp JK, Papadopoulos T, et al. Int J Infect Dis. 2023. S1201-9712(23)00715-4. doi: 10.1016/j.ijid.2023.09.003. Epub ahead of print.
Nationwide measles and rubella outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, et al. Open Forum Infect Dis. 2023;10(2):ofad032.
2022
How Australia's measles control activities have catalyzed rubella elimination.
Glynn-Robinson A, Knapp JK, Durrheim DN. International Journal of Infectious Diseases. 2022;114:72-78. doi: 10.1016/j.ijid.2021.11.003.
Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study.
Winter AK, Lambert B, Klein D, et al. Lancet Glob Health. 2022;10(10):E1412-E1422. doi: 10.1016/S2214-109X(22)00335-7.
Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2012-2020.
Zimmerman LA, Knapp JK, Antoni S, Grant GB, and Reef SE. MMWR Morb Mortal Wkly Rep. 2022;71(6):196-201. doi: 10.15585/mmwr.mm7106a2.
2021
Feasibility assessment of measles and rubella eradication.
Moss WJ, Shendale S, Lindstrand A, et al. Vaccine. 2021;39(27):3544-3559. doi: 10.1016/j.vaccine.2021.04.027.
Progress toward rubella elimination — World Health Organization European Region, 2005–2019.
O’Connor P, Yankovic D, Zimmerman L, Ben Mamou M, Reef S. MMWR Morb Mortal Wkly Rep. 2021;70:833–839. doi: 10.15585/mmwr.mm7023a1.
Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: A metapopulation modelling study.
Su Q, Feng Z, Hao L, et al. Lancet Infect Dis. 2021;21(7):1004-1013. doi: 10.1016/S1473-3099(20)30475-8.
2020
The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization.
Badizadegan K, Goodson JL, Rota PA, Thompson KM. Expert Rev Vaccines. 2020;19(2):175–194. doi: 10.1080/14760584.2020.1732215.
Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study.
Feldstein LR, Bennett SD, Estivariz CF, et al. PLoS Med. 2020;17(3):e1003071. doi: 10.1371/journal.pmed.1003071.
Recent setbacks in measles elimination: The importance of investing in innovations for immunizations.
Goodson JL. Pan Afr Med J. 2020;35(Suppl 1):15. doi: 10.11604/pamj.supp.2020.35.1.21740.
Progress toward rubella elimination — Western Pacific Region, 2000–2019.
Knapp JK, Mariano KM, Pastore R, et al. MMWR Morb Mortal Wkly Rep. 2020;69(24):744–750. doi: 10.15585/mmwr.mm6924a4.
The African Region early experience with structures for the verification of measles elimination — A review.
Masresha B, Luce R, Tanifum P, Lebo E, Dosseh A, Mihigo R. Pan Afr Med J. 2020;35(Suppl 1):1. doi: 10.11604/pamj.supp.2020.35.1.19061.
Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717–1725. doi: 10.4269/ajtmh.20-0112.
The epidemiology of rubella, 2007–2018: An ecological analysis of surveillance data.
Patel MK, Antoni S, Danovaro-Holliday MC, et al. Lancet Glob Health. 2020;8(11):e1399-e1407. doi: 10.1016/S2214-109X(20)30320-X.
A microneedle patch for measles and rubella vaccination: A game changer for achieving elimination.
Prausnitz MR, Goodson JL, Rota PA, Orenstein WA. Curr Opin Virol. 2020;41:68–76. doi: 10.1016/j.coviro.2020.05.005.
2019
Successes and challenges for preventing measles, mumps and rubella by vaccination.
Bankamp B, Hickman C, Icenogle JP, Rota PA. Curr Opin Virol. 2019;34:110–116. doi: 10.1016/j.coviro.2019.01.002.
Genetic characterization of measles and rubella viruses detected through global measles and rubella elimination surveillance, 2016–2018.
Brown KE, Rota PA, Goodson JL, et al. MMWR Morb Mortal Wkly Rep. 2019;68(26):587-591. doi: 10.15585/mmwr.mm6826a3.
Accelerating measles and rubella elimination through research and innovation — Findings from the Measles & Rubella Initiative research prioritization process, 2016.
Grant GB, Masresha BG, Moss WJ, et al. Vaccine. 2019;37(38):5754–5761. doi: 10.1016/j.vaccine.2019.01.081.
Progress toward rubella and congenital rubella syndrome control and elimination — Worldwide, 2000–2018.
Grant GB, Desai S, Dumolard L, Kretsinger K, Reef SE. MMWR Morb Mortal Wkly Rep. 2019;68(39):855–859. doi: 10.15585/mmwr.mm6839a5.
Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey.
Kriss JL, Grant GB, Moss WJ, et al. Vaccine. 2019;37(38): 5745–5753. doi: 10.1016/j.vaccine.2019.02.058.
Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017.
Moro PL, Arana J, Marquez PL, et al. Vaccine. 2019;37(28):3730–3734. doi: 10.1016/j.vaccine.2019.04.088.
Assessment of economic burden of concurrent measles and rubella outbreaks, Romania, 2011–2012.
Njau J, Janta D, Stanescu A, et al. Emerg Infect Dis. 2019;25(6):1101-1109. doi: 10.3201/eid2506.180339.
Selection From Previous Years
Progress and challenges in measles and rubella elimination in the WHO European Region.
Datta SS, O'Connor PM, Jankovic D, et al. Vaccine. 2018;36(36):5408–5415. doi: 10.1016/j.vaccine.2017.06.042.
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
Subaiya S, Tabu C, N'ganga J, et al. PLoS One. 2018;13(7):e0199786. doi: 10.1371/journal.pone.0199786.
Rubella vaccine: A tale of appropriate caution and remarkable success.
Zimmerman LA, Reef SE, Orenstein WA. JAMA Pediatr. 2018;172(1):95–96. doi: 10.1001/jamapediatrics.2017.4178.
2023
Field investigation of high reported non-neonatal tetanus burden in Uganda, 2016–2017.
Casey RM, Nguna J, Opar B. et al. International Journal of Epidemiology. 2023;dyad005.
Tetanus and Diphtheria Seroprotection among Children Younger Than 15 Years in Nigeria, 2018: Who Are the Unprotected Children?
Tohme RA, Scobie HM, Okunromade O, et al. Vaccines. 2023;11(3):663.
2022
Progress toward achieving and sustaining maternal and neonatal tetanus elimination — Worldwide, 2000–2020.
Kanu FA, Yusuf N, Kossague M, Ahmed B, and Tohme RA. MMWR Morb Mortal Wkly Rep. 2022;71:406–411. doi: 10.15585/mmwr.mm7111a2.
Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination — Progress and challenges.
Yusuf N, Steinglass R, Gasse F, et al. BMC Public Health. 2022;22(1):691. doi: 10.1186/s12889-022-13110-2.
2021
The incremental cost, impact and cost-effectiveness of sustaining maternal and neonatal tetanus elimination in 59 priority countries from 2020-2030.
Abstract presentation at: International Health Economics Association Congress; July 12-15, 2021; virtual.
Progress and barriers toward maternal and neonatal tetanus elimination in the remaining 12 countries: A systematic review.
Yusuf N, Raza A, Chang-Blanc D, et al. Lancet Glob Health. 2021;9(11):e1610-e1617. doi: 10.1016/S2214-109X(21)00338-7.
2020
Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016.
Breakwell L, Anga J, Cooley G, et al. Vaccine. 2020;38(30):4679-4686. doi: 10.1016/j.vaccine.2020.05.029.
Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.
Desai S, Scobie HM, Cherian T, Goodman T, Expert Group on the Use of Td vaccine in Childhood. Vaccine. 2020;38(21):3800-3807. doi: 10.1016/j.vaccine.2020.01.018.
Seroprevalence of measles, rubella, tetanus, and diphtheria antibodies among children in Haiti, 2017.
Minta AA, Andre-Alboth J, Childs L, et al. Am J Trop Med Hyg. 2020;103(4):1717-1725. doi: 10.4269/ajtmh.20-0112.
Progress toward maternal and neonatal tetanus elimination - Worldwide, 2000-2018.
Njuguna HN, Yusuf N, Raza AA, Ahmed B, Tohme RA. MMWR Morb Mortal Wkly Rep. 2020; 69(17):515-520. doi: 10.15585/mmwr.mm6917a2.
Selection From Previous Years
High tetanus burden among men—Uganda 2017.
Casey R, Nguna J, Toliva O, et al. International Conference on Emerging Infectious Diseases; August 2018; Atlanta, GA. [page 246]
Notes from the field: Tetanus cases after voluntary medical male circumcision for HIV prevention — Eastern and Southern Africa, 2012–2015.
Grund JM, Toledo C, Davis SM, et al. MMWR Morb Mortal Wkly Rep. 2016; 65(2): 36–37. doi: 10.15585/mmwr.mm6502a5.
Progress towards achieving and maintaining maternal and neonatal tetanus elimination in the African region.
Ridpath AD, Scobie HM, Shibeshi ME, et al. The Pan African Medical Journal. 2017;27(Supp3):24. doi: 10.11604/pamj.supp.2017.27.3.11783.
Tetanus immunity among women aged 15 to 39 years in Cambodia: A national population-based serosurvey, 2012.
Scobie HM, Mao B, Buth S, et al. Clin Vaccine Immunol. 2016;23(7):546-54. doi: 10.1128/CVI.00052-16.
Tetanus immunity gaps in children 5-14 years and men ≥ 15 years of age revealed by integrated disease serosurveillance in Kenya, Tanzania, and Mozambique.
Scobie HM, Patel M, Martin D, et al. Am J Trop Med Hyg. 2017;96(2):415-420. doi: 10.4269/ajtmh.16-0452.
2023
Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction – Worldwide, 2018–2022.
Hancuh M, Walldorf J, Minta AA, et al. MMWR Morb Mortal Wkly Rep. 2023;72(7);171–176. doi 10.15585/mmwr.mm7207a2.
Programmatic effectiveness of a pediatric typhoid conjugate vaccine campaign in Navi Mumbai, India.
Hoffman SA, LeBoa C, Date K, et al. Clinical Infectious Diseases. 2023;ciad132.
2022
Estimating typhoid incidence from community-based serosurveys: A multicohort study.
Aiemjoy K, Seidman J, Saha S, et al. Lancet Microbe. 2022;S2666-5247(22)00114-8. doi: 10.1016/S2666-5247(22)00114-8.
Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: Results of the Surveillance for Enteric Fever in Asia Project.
Garrett D, Longley A, Ajemoy K, et al. Lancet Glob Health. 2022;10(7):e978-e988. doi: 10.1016/S2214-109X(22)00119-X.
Implementation of an outbreak response vaccination campaign with typhoid conjugate vaccine - Harare, Zimbabwe, 2019.
Poncin M, Marembo J, Chitando P, et al. Vaccine. 2022;12:100201. doi: 10.1016/j.jvacx.2022.100201.
Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
Shaum A, Mijuru H, Takamiya M, et al. Vaccine. 2022;40(26):3573-3580. doi: 10.1016/j.vaccine.2022.04.098.
2020
Diagnostic value of clinical features to distinguish enteric fever from other febrile illnesses in Bangladesh, Nepal, and Pakistan.
Aiemjoy K, Tamrakar D, Saha S, et al. Clin Infect Dis. 2020;71(Suppl 3):S257-S265. doi: 10.1093/cid/ciaa1297.
Healthcare utilization patterns for acute febrile illness in Bangladesh, Nepal, and Pakistan: Results from the Surveillance for Enteric Fever in Asia Project.
Andrews JR, Vaidya K, Saha S, et al. Clin Infect Dis. 2020;71(Suppl 3):S248-S256. doi: 10.1093/cid/ciaa1321.
The Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa (SETA), Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) population-based enteric fever studies: A review of methodological similarities and differences.
Carey ME, MacWright WR, Im J, et al. Clin Infect Dis. 2020;71(Suppl 2):S102-S110. doi: 10.1093/cid/ciaa367.
Decision making and implementation of the first public sector introduction of typhoid conjugate vaccine — Navi Mumbai, India, 2018.
Date K, Shimpi R, Lucy S, et al. Clin Infect Dis. 2020;71(Suppl 2):S172-S178. doi: 10.1093/cid/ciaa597.
Utilization of blood culture in South Asia for the diagnosis and treatment of febrile illness.
Hemlock C, Luby SP, Saha S, et al. Clin Infect Dis. 2020;71(Suppl 3):S266-S275. doi: 10.1093/cid/ciaa1322.
Illness severity and outcomes among enteric fever cases from Bangladesh, Nepal, and Pakistan: Data from the Surveillance for Enteric Fever in Asia Project, 2016-2019.
Longley AT, Hemlock C, Date K, et al. Clin Infect Dis. 2020;71(Suppl 3):S222-S231. doi: 10.1093/cid/ciaa1320.
Typhoid and paratyphoid cost of illness in Nepal: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II.
Mejia N, Abimbola T, Andrews JR. Clin Infect Dis. 2020;71(Suppl 3):S306–S318. doi: 10.1093/cid/ciaa1335.
Typhoid and paratyphoid cost of illness in Bangladesh: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II.
Mejia N, Pallas SW, Saha S, et al. Clin Infect Dis. 2020;71(Suppl 3):S293-S305. doi: 10.1093/cid/ciaa1334.
Typhoid and paratyphoid cost of illness in Pakistan: Patient and health facility costs from the Surveillance for Enteric Fever in Asia Project II.
Mejia N, Qamar F, Yousafzai MT, et al. Clin Infect Dis. 2020;71(Suppl 3):S319–S335. doi: 10.1093/cid/ciaa1336.
Methodological considerations for cost of illness studies of enteric fever.
Mejia N, Ramani E, Pallas SW, Song D, Abimbola T, Mogasale V. Clin Infect Dis. 2020;71(Suppl 2):S111-S119. doi: 10.1093/cid/ciaa481.
Antimicrobial resistance in typhoidal salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019.
Qamar FN, Yousafzai MT, Dehraj IF, et al. Clin Infect Dis. 2020;71(Suppl 3):S276-S284. doi: 10.1093/cid/ciaa1323.
Spatial heterogeneity of enteric fever in 2 diverse communities in Nepal.
Tamrakar D, Vaidya K, Yu AT, et al. Clin Infect Dis. 2020;71(Suppl 3):S205-S213. doi: 10.1093/cid/ciaa1319.
Antibiotic use prior to hospital presentation among individuals with suspected enteric fever in Nepal, Bangladesh, and Pakistan.
Vaidya K, Aiemoy K, Qamar FN, et al. Clin Infect Dis. 2020;71(Suppl 3):S285-S292. doi: 10.1093/cid/ciaa1333.
A cluster-based, spatial-sampling method for assessing household healthcare utilization patterns in resource-limited settings.
Yu AT, Shakya R, Adhikari B, et al. Clin Infect Dis. 2020;71(Suppl 3):S239-S247. doi: 10.1093/cid/ciaa1310.
Selection From Previous Years
Lessons learned from emergency response vaccination efforts for cholera, typhoid, yellow fever, and Ebola.
Walldorf JA, Date KA, Sreenivasan N, Harris B, Hyde TB. Emerg Infect Dis. 2017;23(13):S210-S216. doi: 10.3201/eid2313.170550.
